Advanced in Waldenstrom Macroglobulinemia

Yukio Kobayashi

Shiba, JP 
Advanced in Waldenstrom Macroglobulinemia
Shiba, JP 
OverviewLocationsClinical Research

Overview

Yukio Kobayashi practices in Shiba, Japan. Mr. Kobayashi is rated as an Advanced expert by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 113 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Waldenstrom Macroglobulinemia.

Gender
Male

Locations

Shiba, Japan
Other Locations
Tokyo, Japan
Tsukiji, 1040045, Japan
Minato, 1088329, Japan
Chiba, Japan
Chuo, Japan
Tsu, Japan
Hachioji, 1928577, Japan
Kyoto, Japan
Okayama, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2

113 Total Publications

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Journal: Blood advances
Published: January 15, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kobayashi's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile